Akamis Bio’s T-SIGn® therapeutics are based on a replication competent, chimeric group B adenovirus backbone which has been adapted via directed evolution to home specifically to both primary and metastatic epithelial-derived solid tumor tissue following intravenous delivery.
Once at the tumor site, T-SIGn® therapeutics can drive the intratumoral expression of multiple transgene payloads, turning solid tumor cells into “drug factories” while leaving healthy tissue unaltered and intact.
The intratumoral expression of immunologically active biomolecules and therapeutic proteins results in the remodeling of the solid tumor microenvironment and triggering of robust antitumor immune responses which aim to enable a patient’s own immune system to recognize, attack & clear their cancer.
T-SIGn® therapeutics have the potential to be used in the monotherapy setting, as well as in combination with other immuno-oncology agents to target the key mechanisms that tumors use to evade the immune system (e.g., downregulation of tumor antigen presentation, local immunosuppression in the tumor microenvironment, and stromal barriers to immune cell infiltration).
Chemokines Synthetic Payloads
PROPRIETARY VECTOR SYSTEM
Allows up to five transgenes providing tumor-specific expression of novel payload combinations in one treatment modality
Targets primary and metastatic tumors
as a monotherapy or in combination
(e.g with CAR T-cell therapy)
Standard of care or other
(e.g. CAR T-cell therapy)
and Payload Production
Harness endogenous immunity
Express T cell chemo-attractants
Express cytokines, antibodies or other immunomodulators
Cell surface or spray-painted antigens
Activate and direct exogenous therapies
The possibilities are endless.
The combination of Akamis Bio’s T-SIGn® therapeutic design capabilities with our deep expertise in immunology and cancer biology opens the door to a multitude of novel therapeutic immuno-oncology approaches for treating solid tumors.
In addition to T-SIGn® therapeutic-mediated delivery of conventional immunologically active biomolecules and therapeutic proteins (e.g., antibodies, antibody fragments, bispecifics, cytokines, & chemokines), Akamis Bio is also exploring T-SIGn® therapeutics with novel synthetic payload designs with the potential to rationally target specific epithelial derived solid tumor types.
T-SIGn® therapeutics are viral vector based, tumor gene therapies which are capable of homing specifically to primary and metastatic solid tumors following intravenous delivery.
We have a growing pipeline of T-SIGn® therapeutics capable of driving the intratumoral expression of a broad range of therapeutic proteins, as well as immunologically active biomolecules which aim to enable a patient’s immune system to recognize, attack, and clear solid tumors.
Our clinical studies are investigating the use of T-SIGn® therapeutics in the monotherapy setting, as well as in combination with other immuno-oncology agents to target specific solid tumor immune resistance mechanisms.